admin@ataxiatelangiectasia.es
Home
Bibliography
Authors
Cells and molecules
Clinical
Country
Diseases
Drugs
Experimental
Journals
Methods
Year
Resources
What is A-T?
News
Search
News
Quince Therapeutics doses first subject in Ataxia-Telangiectasia trial
Hits: 101
EryDex
Quince Therapeutics
ChromaDex wins orphan designation for rare ataxia drug
Hits: 168
EryDex
Nicotinamide Riboside
ChromaDex
FDA
Nanopore Long-Read Sequencing Facilitates Diagnosis of Atypical Ataxia-Telangiectasia
Hits: 76
Korea
late onset variant
Nanopore
Neurology Genetics
IBEC and AEFAT join forces against ataxia telangiectasia
Hits: 56
Spain
AEFAT
IBEC
Organoids to study ataxia telangiectasia
Hits: 62
Spain
IBEC
organoids
Boston Children's Hospital lab trying to develop drug to treat boy's deadly rare disease
Hits: 83
ASO
U.S. FDA Partial Clinical Hold Lifted on IND for EryDel’s Lead Phase 3 Asset EryDex for the Treatment of Ataxia-Telangiectasia
Hits: 47
EryDex
FDA
Quince Therapeutics
Governor of Queensland Celebrates Ataxia Telangiectasia Clinical Trial
Hits: 45
Australia
Triheptanoin
Acasti reports results from ataxia telangiectasia therapy trial
Hits: 115
GTX-102
Acasti Pharma
A New Model for Neurodegenerative Disease
Hits: 46
pig model
Search
Home
Bibliography
Authors
Cells and molecules
Clinical
Country
Diseases
Drugs
Experimental
Journals
Methods
Year
Resources
What is A-T?
News
admin@ataxiatelangiectasia.es